Friday, 16 October 2026European Markets

IEX GROUP NV Stock Was Up By 11.43% Today

Loading stream...

(VIANEWS) - The Market ended the session with IEX GROUP NV (IEX.AS) jumping 11.43% to €1.95 on Monday while AEX-Index fell 0.63% to €724.18.

IEX GROUP NV's last close was €1.75, 12.5% below its 52-week high of €2.00.

About IEX GROUP NV

IEX Group N.V., through its subsidiaries, operates financial websites in the Netherlands and Belgium. It operates Beurs.nl, Belegger.nl, Beleggen.nl, DeBeurs.nl, Beursonline.nl, Participaties.nl, Beursgorilla.nl, Tostrams.nl and Guruwatch websites. The company also provides investment information services. In addition, the company offers IEX Expert and IEX Profs magazine for various investors; and organizes various events for private individuals and professionals. IEX Group N.V. was founded in 1999 and is based in Amsterdam, the Netherlands.

Earnings Per Share

As for profitability, IEX GROUP NV has a trailing twelve months EPS of €0.25.

PE Ratio

IEX GROUP NV has a trailing twelve months price to earnings ratio of 7.8. Meaning, the purchaser of the share is investing €7.8 for every euro of annual earnings.

Moving Average

IEX GROUP NV's value is higher than its 50-day moving average of €1.88 and way above its 200-day moving average of €1.75.

Volume

Today's last reported volume for IEX GROUP NV is 333 which is 40.32% below its average volume of 558.

More news about IEX GROUP NV (IEX.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com